About Shenzhen Salubris Pharmaceuticals Company

The company was founded in 1998 and listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294). It is an innovation-driven pharmaceutical enterprise based in China, facing the world, integrating R&D, production and marketing. Xinlitai adheres to the sacred mission of “providing excellent pharmaceutical products for human health”, and strives to become a leading enterprise in the field of chronic diseases, mainly cardiovascular and cerebrovascular diseases, with high-quality innovative products and promotion of evidence-based medicine as its core competitiveness. The main business involves R&D, production and sales of pharmaceuticals and medical device products. The main products include cardiovascular drugs and medical devices, cephalosporic antibiotics and raw materials, orthopedic drugs, etc. The research projects cover cardiovascular, hypoglycemic, orthopedic, anti-tumor, and anti-infective treatment fields. Corporate honors: Selected as the top 20 competitive listed Chinese pharmaceutical companies for many years; the top 100 comprehensive strength industrial enterprises in the Chinese chemical pharmaceutical industry; “the 3rd Shenzhen Top 100 Industry Leaders”, etc.